<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00063791</url>
  </required_header>
  <id_info>
    <org_study_id>M34102-052</org_study_id>
    <nct_id>NCT00063791</nct_id>
  </id_info>
  <brief_title>A Study to Assess Two Different Strategies of Combining Dexamethasone and VELCADE</brief_title>
  <official_title>An Open-Labeled, Randomized Study to Assess Two Different Strategies of Combining Dexamethasone and VELCADE in Patients With Relapsed Multiple Myeloma Who Have Failed Four or More Lines of Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Millennium Pharmaceuticals, Inc.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to give patients who have had 4 or more prior lines of therapy&#xD;
      for multiple myeloma access to VELCADE. The study is for patients who are not eligible for&#xD;
      other clinical trials with VELCADE and for who VELCADE would otherwise not be available.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>No longer available</overall_status>
  <study_type>Expanded Access</study_type>
  <condition>Multiple Myeloma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Major Criteria:&#xD;
&#xD;
          -  Plasmacytomas on tissue biopsy&#xD;
&#xD;
          -  Bone marrow plasmacytosis (&gt; 30% plasma cells)&#xD;
&#xD;
          -  Monoclonal IgG is &gt; 3.5 g/dL or IgA is &gt; 2.0 g/dL; kappa or lambda light chain&#xD;
             excretion is &gt; 1 g/day on a 24 hour urine sample.&#xD;
&#xD;
        Minor criteria:&#xD;
&#xD;
          -  Bone marrow plasmacytosis (10 to 30%)&#xD;
&#xD;
          -  Monoclonal immunoglobulin present but of lesser magnitude than given under major&#xD;
             criteria.&#xD;
&#xD;
          -  Lytic bone lesions&#xD;
&#xD;
        Other Eligibility Requirements:&#xD;
&#xD;
          -  Patient is not eligible for Millennium Study M34101-039.&#xD;
&#xD;
          -  Patient has received 4 or more lines of therapy for multiple myeloma and, in the&#xD;
             investigator's opinion, currently needs therapy because of relapsed or progressive&#xD;
             disease.&#xD;
&#xD;
          -  Patient is of legal consenting age, as defined by local regulations.&#xD;
&#xD;
          -  Patient is, in the investigator's opinion, willing and able to comply with the&#xD;
             protocol requirements.&#xD;
&#xD;
          -  Patient has given voluntary written informed consent before performance of any&#xD;
             study-related procedure not part of normal medical care.&#xD;
&#xD;
          -  Female patients must be either post-menopausal, surgically sterilized, or willing to&#xD;
             use an acceptable method of birth control throughout the study.&#xD;
&#xD;
          -  Male patients must agree to use an acceptable method of birth control throughout the&#xD;
             study.&#xD;
&#xD;
          -  Patient has a Karnofsky performance status of greater than or equal to 60%.&#xD;
&#xD;
          -  Patient meets pretreatment laboratory criteria at and within 14 to 21 days before&#xD;
             Baseline (Day 1 of Cycle 1, before study drug administration).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient progressed while receiving VELCADE previously in a clinical trial.&#xD;
&#xD;
          -  Patient has been treated in Millennium Study M34101-039.&#xD;
&#xD;
          -  Patient received corticosteroids (&gt; 10 mg/day prednisone or equivalent) within 1 week&#xD;
             before enrollment in the study.&#xD;
&#xD;
          -  Patient received nitrosoureas within 6 weeks or any other chemotherapy within 3 weeks&#xD;
             before enrollment in the study.&#xD;
&#xD;
          -  Patient received immunotherapy or antibody therapy within 4 weeks before enrollment.&#xD;
&#xD;
          -  Patient had major surgery with 4 weeks before enrollment (kyphoplasty isn't considered&#xD;
             major surgery).&#xD;
&#xD;
          -  Patient has a history of allergic reactions due to compounds containing boron or&#xD;
             mannitol.&#xD;
&#xD;
          -  Patient has peripheral neuropathy of Grade 2 or greater, as defined by the National&#xD;
             Cancer Institute Common Toxicity Criteria (NCI CTC).&#xD;
&#xD;
          -  Patient has a myocardial infarction within 6 months of enrollment or has New York&#xD;
             Heart Association (NYHA) class III or IV heart failure, uncontrolled angina, severe&#xD;
             uncontrolled ventricular arrhythmias or electrocardiogram shows evidence of acute&#xD;
             ischemia or active conduction system abnormalities.&#xD;
&#xD;
          -  Patient has cardiac amyloidosis&#xD;
&#xD;
          -  Patient has poorly controlled hypertension, diabetes mellitus, or other serious&#xD;
             medical or psychiatric illness that could potentially interfere with the completion of&#xD;
             treatment.&#xD;
&#xD;
          -  Patient is known to be infected with human immunodeficiency virus (HIV positive).&#xD;
&#xD;
          -  Patient is known to be hepatitis B positive or has active hepatitis C infection.&#xD;
&#xD;
          -  Patient has an active systemic infection requiring treatment.&#xD;
&#xD;
          -  Female patient is pregnant or breast-feeding. Confirmation that the patient is not&#xD;
             pregnant is required. Pregnancy testing is not required for post-menopausal or&#xD;
             surgically sterilized patients.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Michael Meshad, Oncology Center</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toledo Clinic</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2003</verification_date>
  <study_first_submitted>July 7, 2003</study_first_submitted>
  <study_first_submitted_qc>July 7, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2003</study_first_posted>
  <last_update_submitted>February 13, 2007</last_update_submitted>
  <last_update_submitted_qc>February 13, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 14, 2007</last_update_posted>
  <keyword>Relapsed or Refractory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

